NCT04810676View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 16, 2021

Primary Completion Date

May 20, 2021

Study Completion Date

May 26, 2021

Conditions
Type2 Diabetes Mellitus
Interventions
DRUG

CKD-501, D745, D150

QD, PO

DRUG

CKD-383

QD, PO

Trial Locations (1)

03722

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY